OR WAIT null SECS
The agreement will combine Rentschler’s experience in drug substance manufacturing and Vetter’s expertise in aseptic fill/finish and secondary packaging.
Vetter and Rentschler Biopharma announced on July 6, 2020 that they are entering into a strategic collaboration to increase their services and offer corresponding skills and experience along the biopharmaceutical value chain.
The agreement will combine Rentschler’s experience in drug substance manufacturing and Vetter’s expertise in aseptic fill/finish and secondary packaging, a Vetter press release said. The companies have already identified specific projects to be further validated in pilot client projects with joint teams from both companies as part of the collaboration.
“We are excited to team up with Vetter to complement our customized development and manufacturing solutions for even the most complex biopharmaceuticals,” said Dr. Frank Mathias, CEO of Rentschler Biopharma, in the press release. “Vetter is adding a wealth of expertise for clinical and commercial drug product supply, well suited to the maturing product pipeline of our clients. Their services are a great fit to our own offering. Our collaboration holds great promise for further simplifying client solutions, while expanding the boundaries of what is possible in biopharmaceutical production.”
“There are important synergies between our business portfolios that will provide valuable market foresight that can positively impact our clients’ business and patients’ treatment,” added Peter Soelkner, Managing Director of Vetter, in the press release. “Combining our experience enables us to deliver new efficiencies and pathways that streamline the development and the supply chain in ways that address the challenges of complexity companies across the industry are facing.”